RecruitingPhase 2

Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

China50 participantsStarted 2021-12-01

Plain-language summary

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.

Who can participate

Age range12 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. high risk acute B cell lymphoblastic leukemia with the indications for allogeneic transplantation;
✓. Have matched sibling donors, ≥8/10 HLA matched unrelated donors or haploidentical donors
✓. All patients should aged 12 to 65 years;
✓. Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;
✓. Renal function: creatinine ≤the upper limit of normal;
✓. Patients without any uncontrolled infections , without organ dysfunction or without severe mental illness;
✓. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
✓. Have signed informed consent.

Exclusion criteria

✕. pregnant women;
✕. Patients with mental illness or other states unable to comply with the protocol;
✕. ALL patients with Ph positive;

What they're measuring

Proportion of participants relapse as assessed by NCCN (National Comprehensive Cancer Network ) criteria

Timeframe: 365 days after transplantation

Trial details

NCT IDNCT05088226

SponsorChinese PLA General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-06-01

Contact for this trial

Daihong Liu

86-13681171597 daihongrm@163.com

View on ClinicalTrials.gov More Peripheral Blood Stem Cell Transplantation trials